Exozymes (EXOZ) Other Non-Current Liabilities (2023 - 2026)
Exozymes (EXOZ) posted quarterly Other Non-Current Liabilities of $2.9 million for Q4 2025, down 42.78% quarter-over-quarter from $5.1 million in Q3 2025.
Exozymes (EXOZ) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Other Non-Current Liabilities for 3 consecutive years, with $2.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (changed N/A YoY), while the FY2025 annual figure was $2.9 million, changed N/A from the prior year.
- Other Non-Current Liabilities declined to $2.9 million in Q4 2025 per EXOZ's latest filing, from $5.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.2 million in Q1 2025 and bottomed at $1.0 million in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $4.2 million across 3 years, with a median of $4.0 million in 2025.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 409.87% in 2025 and fell as far as 409.87% in 2025.
- Exozymes' Other Non-Current Liabilities stood at $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then surged by 191.77% to $2.9 million in 2025.
- Business Quant data shows EXOZ's Other Non-Current Liabilities at $2.9 million in Q4 2025, $5.1 million in Q3 2025, and $7.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | 6.99 Mn |
| Mar 31, 2025 | 8.16 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |